New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
09:20 EDTEWEdwards Lifesciences' SAPIEN XT valve approved in EU
Edwards Lifesciences announced it has received CE Mark in Europe for valve-in-valve procedures using the SAPIEN XT transcatheter heart valve, providing a minimally invasive treatment option for patients whose surgical mitral or aortic valves require replacement, and who are at extreme risk for surgery. Edwards is the only company to receive a valve-in-valve indication for the mitral position, which addresses an unmet need within the clinical community to provide an alternative to a high-risk surgery.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2015
16:34 EDTEWEdwards Lifesciences approves two-for-one stock split
Edwards Lifesciences approved a two-for-one split of the company's outstanding shares of common stock to be effected as a 100% stock dividend. This will be the company's second stock split since it went public in April 2000. Stockholders of record at the close of business on November 30 will be issued one additional share of common stock for each share owned as of that date. The additional shares will be distributed on December 11. The stock split will increase the number of common shares outstanding from approximately 108M shares as of the record date, to approximately 216M shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use